AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ABIVAX

Report Publication Announcement Dec 3, 2020

1063_rns_2020-12-03_7972b855-014c-4584-bb0c-87cc92ec52ca.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

News Details

Corporate | 3 December 2020 18:00

Abivax 2021 Financial Communication Calendar

DGAP-News: ABIVAX / Key word(s): Miscellaneous

03.12.2020 / 18:00

The issuer is solely responsible for the content of this announcement.

Abivax 2021 Financial Communication Calendar

PARIS, FRANCE, December 3, 2020 – 6:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar.

  • Thursday, April 1, 2021

    Publication of financial statements as of December 31, 2020

  • Friday, April 30, 2021

    Publication and release of the 2020 annual financial report

  • Friday, June 4, 2021 – 10.00 a.m.

    Shareholders meeting

  • Thursday, September 23, 2021

    Publication of financial statements as of June 30, 2021

  • Thursday, September 30, 2021

    Publication and release of 2021 half year report

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.

Contact s

Abivax

Communications

Regina Jehle

[email protected]

+33 6 24 50 69 63
Investors

LifeSci Advisors

Chris Maggos

[email protected]

+41 79 367 6254
Press Relations & Investors Europe

MC Services AG

Anne Hennecke

[email protected]

+49 211 529 252 22
Public Relations France

Actifin

Ghislaine Gasparetto

[email protected]

+33 6 21 10 49 24
Public Relations France

DGM Conseil

Thomas Roborel de Climens

[email protected]

+33 6 14 50 15 84
Public Relations USA

Rooney Partners LLC

Marion Janic

[email protected]

+1 212 223 4017

03.12.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.